Velmanase alfa
Velmanase alfa, sold under the brand name Lamzede, is a medication for the treatment of alpha-mannosidosis.[1][2]
| Clinical data | |
|---|---|
| Trade names | Lamzede |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Velmanase alfa is a recombinant form of human alpha-mannosidase.[3]
Velmanase alfa was approved for medical use in the European Union in March 2018.[1][3]
References
- "Lamzede EPAR". European Medicines Agency (EMA). Retrieved 25 August 2020.
- Malm D, Nilssen Ø (July 2019) [October 2001]. "Alpha-Mannosidosis". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Mirzaa GM, Amemiya A (eds.). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. PMID 20301570.
- "Chiesi Group receives the European Marketing Authorisation for Lamzede" (Press release). 4 April 2018. Retrieved 24 August 2020.
External links
- "Velmanase Alfa". Drug Information Portal. U.S. National Library of Medicine.
- alpha-Mannosidase at the US National Library of Medicine Medical Subject Headings (MeSH)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.